Alkem Laboratories has launched a triple-drug fixed-dose combination (FDC) of Dapagliflozin, Sitagliptin and Metformin under the brand name of Dapanorm Trio at an affordable price for adults with Type 2 Diabetes in India.

Mohammed Musarif Pasha, Associate Vice President (Sales & Marketing), Alkem said, "A majority of patients in India, pay the cost of the drug from their pockets which makes the drug cost as a major deciding factor in long-term diabetes management. Dapanorm trio is priced at Rs 19.70 per tablet which is almost 70 per cent less compared to the combined cost of innovator drugs."

Alkem received marketing authorization for Dapanorm Trio FDCs based on a phase III multicentric, randomised, double-blind clinical trial (MESIDA trial) which compared the efficacy of triple-drug FDC of Dapagliflozin, sitagliptin and metformin vs combination of Sitagliptin and metformin. The study was conducted on 274 patients with type 2 Diabetes across India. The result of the clinical trial showed that triple drug FDC Dapanorm Trio had superior efficacy in terms of glycemic control as compared to the dual drug combination.